Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mitsugumin-53 (MG53), also known as TRIM72 or tripartite motif-containing protein 72, is a member of the tripartite motif (TRIM) family of proteins. It functions primarily as a membrane repair protein in striated muscle and other tissues. MG53 acts by recruiting essential repair components such as dysferlin and serving as a scaffold to facilitate rapid cell membrane resealing after injury. Mechanistically, it operates both through its E3 ubiquitin ligase activity—targeting proteins like insulin receptor substrate 1 (IRS-1) and focal adhesion kinase for ubiquitination—and by directly participating in the assembly of membrane repair complexes at sites of damage. Recombinant human MG53 (rhMG53) is being developed as a therapeutic agent for conditions involving acute tissue injury and impaired membrane repair such as myocardial infarction, muscular dystrophy, acute kidney injury, and acute lung injury. Preclinical studies have shown that administration of rhMG53 can reduce tissue damage following ischemia-reperfusion events in animal models[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mitsugumin-53.